摘要
慢性肾脏病(CKD)患者通常存在肾素-血管紧张素-醛固酮系统(RAAS)的过度激活,是疾病进展的重要病理生理因素。针对RAAS的干预药物——血管紧张素转换酶抑制剂(ACEI)和血管紧张素Ⅱ受体拮抗剂(ARB),因具有降压和保护靶器官的作用,被广泛用于临床CKD患者的治疗中,也是多数指南推荐的一线药物。但如何合理应用该类药物目前尚未达成一致观点。文章就单独或联合使用ACEI和ARB治疗CKD的效果、药物剂量的选择,以及临床上如何合理应用此类药物等问题的最新观点做一综述。
Over activation of rennin angiotensin aldosterone system （RAAS） usually exists in patients with chronic kidney disease （CKD）, which is an important pathophysiologieal factor for the progression of CKD. As effective inhibitors of RAAS, angiotensin-converting enzyme inhibitor （ACEI） and angiotensin Ⅱ receptor antagonist （ARB） are widely used in clinical treatment of patients with CKD, due to their antihypertensive effects and target organ protection. They are also rec- ommended as the first-line drugs by most guidelines. But how to use of the drugs rationally has not yet reached a consensus. In this review,we discuss the effects of ACEI and ARB used in combination or alone, selection of the dosage, and reasonable prescriptions of them in treatment of CKD.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2014年第9期880-883,共4页
Chinese Journal of Practical Internal Medicine
基金
北京市科学技术委员会科技计划重大项目课题(D131100004713001)
